Teva, Mylan settle Nuvigil patent suit; Warner Chilcott confirms buyer interest;

@FiercePharma: Our latest and greatest ranking of highest-paid CEOs in pharma. Some you'd expect, some you wouldn't. Report | Follow @FiercePharma

> Teva Pharmaceutical Industries ($TEVA) and Mylan ($MYL) came to terms on generic Nuvigil, with a deal allowing Mylan to launch a copy of the wakefulness drug in 2016. Article

> Warner Chilcott ($WCRX) confirmed that it's weighing strategic options, including putting itself on the block, but analysts consider the Irish company more attractive as a buyer than a seller. Report

> As Johnson & Johnson ($JNJ) CEO Alex Gorsky eyes device-company buyouts, analysts suggest that he focus on companies that could augment J&J's cardiovascular business. More

> Biogen Idec ($BIIB) reported a 7% increase in first-quarter revenues, fueled by a 14% rise in revenues of its multiple sclerosis drug Tysabri. News

> Strong sales outside the U.S. helped Hospira ($HSP) deliver profits of $40.2 million, beating analyst estimates. More

> Mylan and Impax prevailed in a patent fight over Warner Chilcott's antibiotic Doryx, allowing Mylan to launch its generic version of the drug. Report

Biotech News

@FierceBiotech: Medidata snags biz from rival Oracle in record Q1. Article | Follow @FierceBiotech

@JohnCFierce: AstraZeneca says so long to half a billion dollars; formally ends Targacept depression deal. Story | Follow @JohnCFierce

@RyanMFierce: Mersana has snagged $4M more for work on next-gen ADCs targeting cancer. More | Follow @RyanMFierce

@MarkHFierce: Could the device tax hurt Minnesota's lead status as a med device employer? Trouble has already come, it seems. Article | Follow @MarkHFierce

> Growing Novo Nordisk inks $100M tech deal, boasts of blockbuster hopefuls. News

> Pfizer turns to late-stage pipeline to make up for Lipitor crash. Article

> AstraZeneca's new iMed R&D team forges first pact with Axerion. Story

> Supernus IPO spotlights perils, potential of going public. More

Medical Devices News

@FierceMedDev: | Follow @FierceMedDev

> St. Jude, Edwards among those named as potential J&J M&A targets. Article

> Breast cancer risk test inches closer to reality. Story

> Hospira sees profits fall 73%. Item

> St. Jude touts safety of leads with Optim insulation. News

Biotech Research News

> Stay calm, folks: Highly anxious mice developed more aggressive cancer. Story

> U-M registers second stem cell line as research fight continues. News

> U.K. scientists map structure of crucial obesity receptor region. Article

> Cleveland Clinic researcher seeks funds to advance breast cancer vaccine into human trials. More

> Potential Alzheimer's treatment disrupts amyloid protein formation. Item

Pharma Manufacturing News

> BASF moves some production from Illinois to Germany. News

> Claris claims it has passed FDA plant inspection. Story

> Haemonetics, Pall ink $550M deal. Article

And Finally... GlaxoSmithKline ($GSK), Roche ($RHHBY) and Novartis ($NVS) earned high grades for sustainable business practices in a ranking by Eiris. Report